Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: Lessons learned from nucleos(t)ide analogues therapy.
暂无分享,去创建一个
[1] Hongwu Tan,et al. A tumour‐promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways , 2017, Clinical and experimental pharmacology & physiology.
[2] Yong-ming Yao,et al. Interleukin-37 Enhances the Suppressive Activity of Naturally Occurring CD4+CD25+ Regulatory T Cells , 2016, Scientific Reports.
[3] M. Pellegrini,et al. The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde , 2016, Clinical & translational immunology.
[4] Xu-dong Liu,et al. Interleukin-21 Is Associated with Early Antiviral Response in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease. , 2016, Journal of Interferon and Cytokine Research.
[5] S. Alavian,et al. Manipulation of Regulatory Cells’ Responses to Treatments for Chronic Hepatitis B Virus Infection , 2016, Hepatitis monthly.
[6] Yan-fang Jiang,et al. Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B. , 2016, World journal of gastroenterology.
[7] S. Tavakolpour. The new insight into management of hepatitis B virus patients with flare. , 2016, Immunology letters.
[8] S. Tavakolpour. Interleukin 21 as a new possible player in pemphigus: Is it a suitable target? , 2016, International immunopharmacology.
[9] S. Alavian,et al. Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review , 2016, Hepatitis monthly.
[10] R. Ueda,et al. Current status of immunotherapy. , 2016, Japanese journal of clinical oncology.
[11] S. Tavakolpour. Inhibition of regulatory cells as a possible cure of chronically hepatitis B virus infected patients. , 2016, Immunology letters.
[12] S. Tavakolpour. Anti-interleukin and associated receptors monoclonal antibodies therapy in autoimmune diseases , 2016 .
[13] H. Fujii,et al. Interleukin-17A Plays a Pivotal Role in Chemically Induced Hepatocellular Carcinoma in Mice , 2016, Digestive Diseases and Sciences.
[14] Y. Xiang,et al. The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis , 2015, PloS one.
[15] Cheng-song Sun,et al. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy , 2015, Acta Pharmacologica Sinica.
[16] Lemonica Koumbi. Current and future antiviral drug therapies of hepatitis B chronic infection. , 2015, World journal of hepatology.
[17] Wenhong Zhang,et al. Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment , 2015, Antimicrobial Agents and Chemotherapy.
[18] Wang-xian Tang,et al. Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses , 2015, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.
[19] X. Liu,et al. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance , 2015, Cell Death and Disease.
[20] S. Manzoor,et al. IL-22: a promising candidate to inhibit viral-induced liver disease progression and hepatocellular carcinoma , 2015, Tumor Biology.
[21] V. Wong,et al. Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B , 2014, Journal of viral hepatitis.
[22] M. Ota,et al. Serum levels of interleukin‐22 and hepatitis B core‐related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.
[23] S. Kottilil,et al. Strategies to eliminate HBV infection. , 2014, Future virology.
[24] Jinhong Chang,et al. Therapeutic strategies for a functional cure of chronic hepatitis B virus infection , 2014, Acta pharmaceutica Sinica. B.
[25] M. El-Houseini,et al. Potential immunotherapeutic role of interleukin-2 and interleukin-12 combination in patients with hepatocellular carcinoma , 2014, Journal of hepatocellular carcinoma.
[26] Jun Yu,et al. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. , 2014, World journal of gastroenterology.
[27] G. Xiao,et al. Prevalence and Clinical Relevance of T-Helper Cells, Th17 and Th1, in Hepatitis B Virus-Related Hepatocellular Carcinoma , 2014, PloS one.
[28] K. Chayama,et al. Serum interleukin‐6 associated with hepatocellular carcinoma risk: A nested case–control study , 2014, International journal of cancer.
[29] M. Arababadi,et al. Current information concerning association of IL-12 and hepatitis B infection. , 2014, Clinical Laboratory.
[30] A. Busca,et al. Innate immune responses in hepatitis B virus (HBV) infection , 2014, Virology Journal.
[31] Han‐Chieh Lin,et al. Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments , 2013, International journal of cancer.
[32] M. Zheng,et al. Emerging Role of Interleukin 22 in Hepatitis B Virus Infection: a Double-edged Sword , 2013, Journal of clinical and translational hepatology.
[33] A. Bertoletti,et al. Immune Therapeutic Strategies in Chronic Hepatitis B Virus Infection: Virus or Inflammation Control? , 2013, PLoS pathogens.
[34] S. Sarin,et al. Immunological mechanisms of hepatitis B virus persistence in newborns , 2013, The Indian journal of medical research.
[35] J. Lian,et al. Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic hepatitis B. , 2013, Viral immunology.
[36] Yanfang Jiang,et al. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment. , 2013, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[37] Li-na Ma,et al. Extended treatment with peginterferon α‐2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion , 2013, Journal of digestive diseases.
[38] Jing Zhao,et al. IL-17A but not IL-22 suppresses the replication of hepatitis B virus mediated by over-expression of MxA and OAS mRNA in the HepG2.2.15 cell line. , 2013, Antiviral research.
[39] J. Luk,et al. Interleukin 23 Promotes Hepatocellular Carcinoma Metastasis via NF-Kappa B Induced Matrix Metalloproteinase 9 Expression , 2012, PloS one.
[40] B. Ni,et al. Effects of Telbivudine Treatment on the Circulating CD4+ T-Cell Subpopulations in Chronic Hepatitis B Patients , 2012, Mediators of inflammation.
[41] Zhi‐hua Liu,et al. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. , 2012, Journal of hepatology.
[42] Y. Li,et al. Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B. , 2012, Viral immunology.
[43] H. Ren,et al. Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients , 2012, Clinical and Experimental Medicine.
[44] Younhee Park,et al. Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy , 2011, Journal of clinical laboratory analysis.
[45] D. Hedley,et al. Tenofovir Selectively Regulates Production of Inflammatory Cytokines and Shifts the IL-12/IL-10 Balance in Human Primary Cells , 2011, Journal of acquired immune deficiency syndromes.
[46] Lanjuan Li,et al. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. , 2011, Antiviral research.
[47] D. Long,et al. Increased Frequency of CD4+CD25highFoxP3+ Regulatory T Cells in Patients with Hepatocellular Carcinoma , 2011, Archivum Immunologiae et Therapiae Experimentalis.
[48] Y. Hiasa,et al. Mechanism of restoration of immune responses of patients with chronic hepatitis B during lamivudine therapy: increased antigen processing and presentation by dendritic cells , 2011, Journal of viral hepatitis.
[49] Steven‐Huy B. Han,et al. Combination Therapy for Chronic Hepatitis B: Current Indications , 2011, Current hepatitis reports.
[50] S. Sarin,et al. Circulating Tregs Correlate with Viral Load Reduction in Chronic HBV-Treated Patients with Tenofovir Disoproxil Fumarate , 2011, Journal of Clinical Immunology.
[51] J. Yeon,et al. HBsAg Seroclearance in Chronic Hepatitis B: Implications for Hepatocellular Carcinoma , 2011, Journal of clinical gastroenterology.
[52] J. Niu,et al. Th1 and Th2 Immune Response in Chronic Hepatitis B Patients during a Long-Term Treatment with Adefovir Dipivoxil , 2010, Mediators of inflammation.
[53] Jiyuan Zhang,et al. Decreased Ratio of Treg Cells to Th17 Cells Correlates with HBV DNA Suppression in Chronic Hepatitis B Patients Undergoing Entecavir Treatment , 2010, PloS one.
[54] H. Janssen,et al. The Role of Interferon in Hepatitis B Therapy , 2010, Current hepatitis reports.
[55] A. Lok,et al. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. , 2009, Journal of hepatology.
[56] B. Becher,et al. IL-9 as a mediator of Th17-driven inflammatory disease , 2009, The Journal of experimental medicine.
[57] N. Terrault. Benefits and risks of combination therapy for hepatitis B , 2009, Hepatology.
[58] Mong-Liang Chen,et al. HBV replication is significantly reduced by IL-6 , 2009, Journal of Biomedical Science.
[59] N. Terrault. Benefits and Risks of Combination Therapy for Hepatitis , 2009 .
[60] S. Chokshi,et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e‐antigen seroconversion , 2008, Hepatology.
[61] Dong-yun Zhang,et al. Effects of lamivudine on the function of dendritic cells derived from patients with chronic hepatitis B virus infection. , 2007, World journal of gastroenterology.
[62] E. Kuipers,et al. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. , 2007, Virology.
[63] R. Flavell,et al. IL9 leads to airway inflammation by inducing IL13 expression in airway epithelial cells. , 2006, International immunology.
[64] J. G. Kusters,et al. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV , 2006, Hepatology.
[65] L. Ye,et al. Pathogenesis of hepatitis B virus infection , 2006 .
[66] P. Lipsky,et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. , 2006, Blood.
[67] Roger Williams,et al. Lamivudine plus interleukin‐12 combination therapy in chronic hepatitis B: Antiviral and immunological activity , 2005, Hepatology.
[68] G. Doria,et al. IL-4 Modulation of CD4+CD25+ T Regulatory Cell-Mediated Suppression1 , 2005, The Journal of Immunology.
[69] E. Kuipers,et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection , 2005, Hepatology.
[70] C. Siu,et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects , 2004, Hepatology.
[71] B. Nelson. IL-2, Regulatory T Cells, and Tolerance , 2004, The Journal of Immunology.
[72] M. Bajénoff,et al. IL-4-mediated inhibition of IFN-gamma production by CD4+ T cells proceeds by several developmentally regulated mechanisms. , 2004, International immunology.
[73] D. Cantrell,et al. Sustained IL-12 Signaling Is Required for Th1 Development 1 , 2004, The Journal of Immunology.
[74] Ching-Lung Lai,et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.
[75] Sue-Jane Lin,et al. IL-4 Suppresses the Expression and the Replication of Hepatitis B Virus in the Hepatocellular Carcinoma Cell Line Hep3B 1 , 2003, The Journal of Immunology.
[76] M. Biermer,et al. Tumor Necrosis Factor Alpha Inhibition of Hepatitis B Virus Replication Involves Disruption of Capsid Integrity through Activation of NF-κB , 2003, Journal of Virology.
[77] M. Biermer,et al. Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB. , 2003, Journal of virology.
[78] V. Calvez,et al. Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus–infected patients: Results from a randomized control trial , 2002, Hepatology.
[79] F. Chisari,et al. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice , 1997, Journal of virology.
[80] N. Horiike,et al. Effect of recombinant interleukin 2 on hepatitis B e antigen positive chronic hepatitis. , 1987, Gut.